Dr Mike Catton is an APPRISE collaborator and the Director of the Victorian Infectious Diseases Reference Laboratory (VIDRL), and Co-Deputy Director of the Doherty Institute. He trained in microbiology, then medicine at the University of Otago in New Zealand, and received his Fellowship of the Royal College of Pathologists of Australasia (RCPA) in virology in 1992. He has been Director of VIDRL since 2001.
Dr Catton’s professional interests are in molecular viral diagnostics, high containment laboratory facilities and emerging viruses. He has served on diverse advisory committees related to public health and infectious diseases, to the Victorian and Australian governments, the RCPA, and WHO, and has consulted for WHO internationally. He was cofounder and founding Vice-President of the Association for Biosafety of Australia and New Zealand (ABSANZ). He currently serves on the advisory committee of the Victorian Donor Tissue Bank.
Find out more about Dr Catton and his key achievements and publications.
Read more about an APPRISE COVID-19 project – National and targeted sero-surveys of population immunity to SARS-COV2 to inform clinical and public health responses.
- Developing Australasia’s serological capability for viral haemorrhagic fevers
- Human parechovirus 3 (HPeV3) recombinant strain diversity and severe disease association in Australian outbreaks
- Sampling, shipping and serology: a proof of concept study of influenza immunity
- Sentinel Travellers and Research Preparedness Platform for Emerging Infectious Disease (SETREP-ID)
- Evaluation of 6 commercial SARS-CoV-2 serology assays detecting different antibodies for clinical testing and serosurveillance
- Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
- Tracking the COVID-19 pandemic in Australia using genomics
- Isolation and rapid sharing of the 2019 novel coronavirus (SARS ‐CoV‐2) from the first patient diagnosed with COVID ‐19 in Australia
- Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19